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agreement with these observations, the
authors also demonstrated that skin
inflammation and IL-17 expression in
R258W mutant mice were decreased
in vivo when animals were treated with
IL1b antibodies. Interestingly, IL17 anti-
bodies also improved skin pathology,
therefore arguing for an important IL-1b-
IL-17 axis in disease progression, at least
in cutaneous tissues.
At the cellular level, both groups iso-
lated bone marrow-derived macrophages
(BMDMs; Meng et al. [2009]) or bone
marrow-derived dendritic cells (BMDCs;
Brydges et al. [2009]) from mutant mice
and explored their IL-1b-dependent re-
sponse after exposure to TLR ligands in
the presence or absence of ATP. Both
studies showed that myeloid cells from
mutant mice did not secrete mature IL-
1b spontaneously, but displayedaconsid-
erably higher sensitivity to TLR ligands
than WT cells and, importantly, did not
require exogenous addition of ATP for
optimal activation (Figure 1). This latter
finding is important, because it supports
the notion that NLRP3 mutations associ-
ated with disease susceptibility are gain-
of-function mutations, and that the
mutated NLRP3 protein is constitutively
active and therefore does not require
detection of upstream stimuli. However,
neither study addressed the critical ques-
tion of whether TLR-dependent accumu-
lation of pro-IL1b transcripts is also re-
quired in vivo to ignite IL-1b secretion in
Nlrp3 mutant mice. Indeed, this mode of
activation can be envisioned for tissues
such as the skin, which might come in
contact with microbes after wounding. It
does not explain, however, why Nlrp3
mutantmice did not develop inflammation
in the intestine and the lung, which are co-
nstantly exposed tomicrobes. This obser-
vation suggests that microbial tolerization
mechanisms may efficiently suppress in-
flammasome activation in mucosal sur-
faces in contact with microbes in homeo-
static conditions.
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In this issue of Immunity, Miyara et al. (2009) demonstrate that FoxP3+ cells in human peripheral blood are
heterogeneous in function, and CD45RA expression defines their different stages of differentiation.Immunity 30, June 19, 2009 ª2009 Elsevier Inc. 763CD4+CD25++FoxP3+ Treg cells are pivotal
in controlling undesired self and non-self
immune responses. Importantly, FoxP3+
Treg cells may not be a functionally
homogenous population. Various human
Treg cell subtypes within peripheral
CD4+FoxP3+ T cells have been identified
and can be subgrouped based on the
expression of CD45RA (Seddiki et al.,
2006; Valmori et al., 2005), HLA-DR
(Baecher-Allan et al., 2006), and ICOS (Ito
et al., 2008). Furthermore, FoxP3 can be
expressed in T cells without conferring
regulatory properties. Until now, the dyna-
mic differentiation and fate of the various
FoxP3-expressinghumanperipheralCD4+T cells remained to be clarified. Miyara
et al. (2009) in this issue of Immunity
show that human CD4+FoxP3+ T cells
comprise three distinct subpopulations
with a precise phenotype and fate:CD25++
CD45RA+ (FOXP3lo) resting Treg cells
(rTreg cells), CD25+++CD45RA(FOXP3hi)
activated Treg cells (aTreg cells), which
represent different stages of Treg cell
differentiation and are both suppressive
in vitro, and CD25++CD45RA(FOXP3lo)
cytokine secreting T cells, which lack
suppressive activity.
Positively selected T cells express
CD45RO in the thymus, convert to
CD45RA expression at the time of periph-eral migration, and switch back to
CD45RO after antigen (Ag) recognition. A
small percentage of Ag-experienced
T cells revert from CD45RO+ to CD45RA+
as they undergo differentiation into
terminal effector cells. Initially, it was
thought that, in adult peripheral blood,
CD4+CD25+++ Treg cells reside predomi-
nantly within the activated memory
CD45RA cell subset and within the naive
CD45RA+ cell subset in the cord blood.
Subsequently, the presence of CD45RA+
Treg cells, in addition to CD45RA Treg
cells, was appreciated in the periphery of
adults (Seddiki et al., 2006; Valmori
et al., 2005). Fritzching et al. (2006)
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PreviewsFigure 1. FoxP3+ Treg Cell Fate
Human Treg cells depart from the thymus as resting Treg (rTreg) cells expressing CD31, CD45RA, inter-
mediate amounts of CD25, and low amounts of FOXP3. Upon peripheral Ag encounter, rTreg cells prolif-
erate, downregulate CD45RA, upregulate CD25, FOXP3, CTLA-4, HLA-DR, and ICOS expression and
become activated Treg (aTreg) cells that suppress proliferation of conventional T cells (Tconv). aTreg cells
are short lived and rapidly die after activation and suppression. Highly proliferating aTreg cells suppress
also proliferation of rTreg cells generating a negative feedback loop that stops rTreg cell conversion into
aTreg cells and consequent Treg cell exhaustion. It remains to be defined whether: (1) there is a life-long
thymic output of CD45RA+ rTreg cells or they are self-maintained; (2) a portion of aTreg cells survive and
become memory long-living aTreg cells; and (3) aTreg cells make use of different suppressive mecha-
nisms to inhibit proliferation of Tconv and rTreg cells.demonstrated that CD45RA+ Treg cells
are resistant to CD95L-mediated ap-
optosis whereas CD45RA Treg cells
rapidly die after activation. In line with
this finding, only CD45RA+ Treg cells
gave rise to homogenous regulatory
T cell lines upon in vitro expansion (Hoff-
mann et al., 2009). Although their relation-
ship remained unclear, CD45RA+ and
CD45RA Treg cells were reported to
have comparable function. This was quite
surprising, because, in principle, naiveAg-
inexperienced CD45RA+ T cells and
memory Ag-primed CD45RA T cells
should exhibit different functions. In the
present study, Miyara et al. (2009) confirm
both the phenotypical characterization of
human peripheral Treg cells based on
CD25 and CD45RA expression (Fritzsch-
ing et al., 2006; Haas et al., 2007; Seddiki
et al., 2006; Valmori et al., 2005) and the
apopotosis susceptibility of CD45RA
Treg cells (Fritzsching et al., 2006). In addi-
tion, in line with previous studies (Seddiki
et al., 2006; Valmori et al., 2005), they764 Immunity 30, June 19, 2009 ª2009 Elsealso demonstrate that the ability of
CD45RA+ rTreg cells and CD45RA aTreg
cells to suppress conventional T cells is
comparable. However, the gene expres-
sion patterns of these two Treg cell
subsets are distinct, suggesting different
suppressive mechanisms. aTreg cells are,
for instance, more active in IL-10 tran-
scription but less active in TGF-b, as
compared to rTreg cells. Furthermore, in
the present study, it is shown that aTreg
cells can inhibit proliferation of rTreg cells.
The key finding of Miyara et al. (2009) is
the demonstration that CD45RA+ rTreg
cells and CD45RA aTreg cells represent
a distinct differentiation status of the
same T cells. This is proven by an elegant
experiment in which clonotypes within the
CD45RA+ rTreg cells and CD45RA aTreg
cells were tracked in vivo 18months apart
in the same individual. A clonotype initially
detected only in the rTreg cells was found
18 months later to be dominant in the
aTreg cells. We can therefore hypothesize
that: (1) the thymus generates CD45RA+vier Inc.rTreg cells, which are either constantly
thymically generated or self-maintained
(still to be determined); (2) CD45RA+ rTreg
cells, once activated through their TCR,
rapidly proliferate and become CD45RA
aTreg cells that can suppress conven-
tional T cells and die (whether a portion
of aTreg cells survive and become a
memory long-living Treg cells is still to
be clarified); (3) actively dividing aTreg
cells can also suppress proliferation of
rTreg cells, generating a negative feed-
back loop that stops rTreg cell conversion
into aTreg cells and consequent Treg cell
exhaustion (Figure 1). This model, sup-
ported by the data presented by Miyara
et al. (2009), sheds light on the in vivo
cell fate and dynamic differentiation of
different human FoxP3+ Treg cell subsets.
However, a number of key questions
remain to be addressed. Do rTreg cells
and aTreg cells use different mechanisms
of suppression? Miyara et al. (2009) show
that both Treg cell types suppress T cell
proliferation in vitro, but themechanism(s)
underlying this suppression is not eluci-
dated and the role of cytokines is not
addressed. Do rTreg and aTreg cells
reside in different tissues? All the experi-
ments by Miyara et al. (2009) were per-
formed with peripheral blood and the
presence of these different Treg cell types
in the spleen, lymph nodes, or tissues has
not been demonstrated. Finally, what is
the relationship between the two Treg
cell subsets here described and the
inducible Treg cells reported by others?
The fact that activated Treg cells
described by Miyara et al. (2009) are
superimposable to the previously des-
cribed CD25+++ HLA-DR+ (Baecher-Allan
et al., 2006) and the ICOS+ FoxP3+ (Ito
et al., 2008) Treg cells, both in term of
phenotype and function, remains, in our
opinion, uncertain. The HLA-DR+-acti-
vated Treg cells were shown to induce
early contact dependent in vitro suppres-
sion (Baecher-Allan et al., 2006), whereas
the ICOS+-activated Treg cells use IL-10
to suppress DC function and TGF-b to
suppress T cells (Ito et al., 2008).
Initial studies reported reciprocally regu-
lated andmutually exclusive differentiation
programs for Treg cells and Th17 cells.
However, the relationship between Treg
cells and Th17 cells might be more com-
plex than anticipated, involving plasticity
of the respective differentiation programs
mediated by epigenetic mechanisms. The
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recent demonstration that cells coex-
pressing the master regulator genes for
Treg cells (i.e., FoxP3) and for Th17 cells
(i.e., the retinoic acid-related orphan
receptor gamma t, RORgt) exist (Ayyoub
et al., 2009; Voo et al., 2009) and they are
members of the CD45RA aTreg cell
subset. The interesting finding relies on
the observation that CD45RA aTreg
cells express, together with RORgt, high
amounts of theAryl hydrocarbon receptor-
repressor (AHR-R),which inhibits Th17cell
differentiation. These new data demon-
strate the plasticity of CD4+ T cells whose
fate is defined by finely tuned genetic and
epigenetic states of critical regulators
that skew them toward opposite T cell
lineages.
Of particular interest is the wide variety
of human autoimmune diseases in which
a defect in the Treg cell function has
been demonstrated, raising the inter-
esting possibility that this may be a
common denominator causing uncon-
trolled immune responses to self Ags.
However, presently there is no consensus
on the functional status of Treg cells in
human autoimmune diseases. The dyna-
mic change of circulating CD45RA+ rTreg
cells into CD45RA aTreg cells here
described (Miyara et al., 2009) might
be of help to better interpret previously
conflicting results. Haas et al. (2007)
demonstrated that peripheral CD45RA+
rTreg cells are reduced in multiple scle-
rosis (MS) patients and this might account
for the diminished suppressive Treg cell
potency observed in MS individuals.
Miyara et al. (2009) find that patients
with active sarcoidosis, a granulomatousdisease of unknown origin, have ex-
panded aTreg cells whereas patients
with active systemic lupus erythemato-
sus (SLE), a prototype of autoimmune
disease, have increased rTreg cells and
FoxP3+ non-Treg cells, as compared to
age-matched controls. Overall, these re-
sults prove that the field remains complex
and needs further exploration.
Finally, the present work (Miyara et al.,
2009) challenges three of the widely
accepted notions in the Treg cell field,
providing important technical advances.
First, human Treg cells are not anergic
in vitro but, upon TCR-mediated activa-
tion, proliferate and the majority die. This
finding implies that the thymidine uptake
method commonly used for monitoring
the in vitro suppressive ability of Treg
cells may not be ideal and results may
be confounded by the fact that aTreg
cells suppress rTreg cells and that
aTreg cells die. Second, CD127, which
is used as a surface marker to isolate
bona fide human Treg cells by flow
cytometry, is not a specific marker.
CD4+CD25+CD127lo T cells indeed
include also FoxP3+ cells that produce
IL-17, high amounts of IL-2 and IFN-g,
and do not suppress. CD25 and CD45RA
markers should therefore be used to avoid
isolation of FoxP3+ non-Treg cells. Finally,
cord blood CD4+CD25+ T cells are not all
FoxP3+ as previously reported (Fritzsch-
ing et al., 2006) and, in addition,
RAFOXP3hi aTreg cells are also present
in cord blood. These data prove that
natural Treg cells are constantly activated
by endogenous self and maternal Ag even
in utero and raises some question on the
cord blood Treg cell ‘‘naiveness.’’ImmunityOverall, the present study sheds light
on the tangled and controversial world
of human Treg cells but also brings an
additional layer of complexity in the
phenotypical and functional characteriza-
tion of these cells.
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